- The key vendors in the Epilepsy Therapeutics Market in APAC Region 2015-2019 are Eisai Inc., GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
London, 23 December 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Epilepsy Therapeutics Market in APAC Region 2015-2019. The reformulation of marketed drugs is one key trend emerging in the market. Reformulated drugs usually have better tolerability and better dosage regimens than the original drugs and this increases the acceptance of such drugs and increases the revenue generated through their sales. The Epilepsy Therapeutics market in the APAC region is expected to post a CAGR of 5.78 percent during the period 2014-2019.
The reformulation of a drug increases the possibility of the number of patients that can undergo treatment with a specific drug, thereby increasing its revenue. The launch of recently approved drugs is expected to drive the market in the APAC region during the forecast period.
“The market strategy of major vendors to penetrate emerging markets in the APAC region and to implement increased healthcare reforms is expected to change the treatment regimen for epilepsy,” says Faisal Ghaus, Vice President of TechNavio Research.
“Introduction of a few third-generation epilepsy drugs such as lacosamide is also fueling growth of the market in the APAC region.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
